BioSpace News Archive

TC BioPharm PLC announced the closing of its previously announced private placement for the issuance and sale of 1,470,000 American Depositary Shares, Series A warrants to purchase up to an aggregate of 1,470,000 ADSs and Series B warrants to purchase up to an aggregate of 1,470,000 ADSs at a purchase price of $5.00 per ADS and associated warrants.

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the pricing of an underwritten public offering of 6,700,000 shares of its common stock at a price to the public of $12.00 per share.

IVERIC bio, Inc., announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions.

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the launch of an underwritten public offering of its common stock.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN.

Arcadia Biosciences, Inc.®, a producer and marketer of innovative, plant-based health and wellness products, announced that CFO Pam Haley will be leaving the company and will be replaced by Thomas J. Schaefer, effective January 3, 2023.

Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains.

Enochian BioSciences Inc. received a notice from The Nasdaq Stock Market LLC stating that because the Company has not yet filed its Form 10-Q for the period ended September 30, 2022, the Company remains in non-compliance with Nasdaq Listing Rule 5250, which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.